![]() |
GSK3326595
- 英文名称:GSK3326595
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11073
- cas:1616392-22-3
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-12
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11073 |
用途 | 科研检测 |
英文名称 | GSK3326595 |
包装规格 | 1MG |
CAS编号 | 1616392-22-3 |
别名 | GSK3326595 |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:98% by HPLC;NMR (Conforms)
分子式:C24H32N6O3
分子量:452.56
溶剂:DMSO (20 mg/ml)
性状:Off-white solid
存储:-20°C
Activity (short version):PRMT5 inhibitor
Function / Pharmacology:GSK3326595 is a potent (IC50 = 6.2nM), selective (>4000-fold over 20 other methyltransferases), SAM uncompetitive, peptide competitive inhibitor of PRMT5.1 PRMT5 inhibition activated the p53 pathway via induction of alternative splicing of MDM4 leading to a potent anti-proliferative response both in vitro and in vivo. Combination therapy with palbociclib (CDK4/6 inhibitor, Focus Cat.# 10-4760) and GSK3326595 lead to increased efficacy of palbociclib in treating native and resistant models of melanoma via regulation of the PRMT5-MDM4 axis.2 Currently in clinical Trials.3
分子式:C24H32N6O3
分子量:452.56
溶剂:DMSO (20 mg/ml)
性状:Off-white solid
存储:-20°C
Activity (short version):PRMT5 inhibitor
Function / Pharmacology:GSK3326595 is a potent (IC50 = 6.2nM), selective (>4000-fold over 20 other methyltransferases), SAM uncompetitive, peptide competitive inhibitor of PRMT5.1 PRMT5 inhibition activated the p53 pathway via induction of alternative splicing of MDM4 leading to a potent anti-proliferative response both in vitro and in vivo. Combination therapy with palbociclib (CDK4/6 inhibitor, Focus Cat.# 10-4760) and GSK3326595 lead to increased efficacy of palbociclib in treating native and resistant models of melanoma via regulation of the PRMT5-MDM4 axis.2 Currently in clinical Trials.3